The SESN2 (Sestrin2) antibody is a valuable tool in biomedical research, targeting the stress-inducible protein SESN2 involved in cellular stress responses and metabolic regulation. SESN2 belongs to the Sestrin family of evolutionarily conserved proteins that function as antioxidants and regulators of mTORC1 (mechanistic target of rapamycin complex 1) signaling. It is primarily activated under oxidative stress, DNA damage, or hypoxia via p53-dependent or independent pathways, playing a dual role in cytoprotection and tumor suppression. SESN2 modulates cellular homeostasis by inhibiting mTORC1 activity, thereby influencing autophagy, apoptosis, and metabolic reprogramming.
Antibodies against SESN2 are widely used to study its expression patterns, subcellular localization, and interactions in conditions like cancer, neurodegenerative diseases, and metabolic disorders. They enable detection via Western blotting, immunohistochemistry, and immunofluorescence, aiding in understanding SESN2's role in stress adaptation, aging, and disease progression. Research highlights SESN2's potential as a therapeutic target, particularly in cancers with dysregulated mTOR pathways or oxidative stress vulnerabilities. Both polyclonal and monoclonal SESN2 antibodies are available, with validation in specific experimental models critical for ensuring specificity. Ongoing studies focus on clarifying its pleiotropic functions, including links to inflammation, insulin resistance, and mitochondrial health, underscoring its relevance in translational medicine.